English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThree clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.
Tag: Stem Cell Transplant
Multi-center study shows education level, income impact access to stem cell transplantation for acute myeloid leukemia patients
Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.
New drug tested to reduce side effect of ‘half-matched’ stem cell transplants
Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a clinical trial conducted by researchers at WashU Medicine showed adding the investigational drug itacitinib to standard care for “half-matched” stem cell transplantation may reduce rates of the disease, in which the donor’s stem cells attack the patient’s healthy tissues.
Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer
Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
CHOP Researchers Improve Fitness of Cells Used in Cell Transplants
A readily available, inexpensive small molecule drug can improve the fitness of hematopoietic stem and progenitor cells (HSPCs) that are modified outside of the body, potentially improving the success of procedures like ex vivo gene therapy, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP).
Cell Therapy That Repairs Cornea Damage with Patient’s Own Stem Cells Achieves Positive Phase I Trial Results
Cultivated autologous limbal epithelial cells (CALEC) transplant, in which stem cells from the healthy eye and transplanted into the injured eye, for significant cornea injuries was found safe and led to gains in preliminary phase I clinical trial.
CHOP Researchers Develop Tool that Reduces Errors in Stem Cell Transplant Reporting
Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and at the same time substantially improves accuracy of reported hematopoietic cell transplant engraftments.
Triple-drug therapy for post-transplant management of multiple myeloma
Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.
UChicago Medicine earns high marks for stem cell transplant survival rates
New data show the University of Chicago Medicine’s David and Etta Jonas Center for Cellular Therapy has the highest one-year survival rate in Illinois for adults undergoing blood and bone marrow stem cell transplants. UChicago Medicine had an 80% one-year survival rate among adult stem cell patients, according to the latest statistics released in mid-December by the Center for International Blood & Marrow Transplant Research (CIBMTR).
A Leading-Edge Lymphoma Program
Less than three years after joining the Cedars-Sinai Cancer faculty, hematologist-oncologists Justin Darrah, MD, and Akil Merchant, MD, are pioneering new research and bringing a new, comprehensive set of treatment options to patients in the recently established Lymphoma Program.
COVID-19 vaccine effective in people receiving cancer treatment, study finds
About 95% of participants achieved a measurable immune response after vaccination, according to study published in JAMA Oncology.
Three Steps Forward
Mariah Candelaria is a three-time survivor of Hodgkin Lymphoma and received a stem cell transplant at the University of New Mexico Comprehensive Cancer Center. During and after her recovery she’s leaned on dance to make it through. Now she wants to give back to others who are going through similar challenges fighting cancer.
Hematopoietic Stem Cell Transplants May Provide Long-Term Benefit for People with MS
A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment. Additionally, more than half of the people with the secondary progressive form of MS experienced no worsening of their symptoms 10 years after a transplant.
Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.
Donor stem cell transplant shown to improve survival in older patients with myelodysplastic syndrome
A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting
Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.
Roswell Park Study: Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients
Patients who develop cytomegalovirus infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system and reduce reliance on strong antiviral medications, a team from Roswell Park reports in the journal Biology of Blood and Marrow Transplantation.
Memorial Sloan Kettering – Hackensack Meridian Health Partnership Announces Funding for Inaugural Immunology Research Collaboration Projects
The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers’ projects were selected in 2020 for funding support.
Mutations in donors’ stem cells may cause problems for cancer patients
A new study from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells — though not causing health problems in the donors — may be passed on to cancer patients receiving stem cell transplants, potentially creating health problems for the recipients. Among the concerns are heart damage, graft-versus-host disease and possible new leukemias.
Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.
Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.
Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.
‘It’s not about just surviving. It’s about seeing my patients living normally’
Dr. Eugene Chang was 25, recently engaged and halfway through a physical medicine and rehabilitation residency in Vancouver when he started feeling sick. Fatigue, dizziness and nausea took over his normally active lifestyle. Suddenly his bike to work was not so easy.